Hem › Melanom › Kalifornien › Los Angeles
Kliniska studier för Melanom i Los Angeles, CA
34 studier för Melanom söker deltagare vid platser i och runt Los Angeles (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
RekryterarFas 1/2
- The Angeles Clinic and Research Institute (Melanoma), Los Angeles
- USC Norris Comprehensive Cancer Center (Melanoma/NSCLC), Los Angeles
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RekryterarFas 3
- University of California Los Angeles, Los Angeles
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekryterarFas 2
- The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- och 1 fler
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekryterarFas 1/2
- University of Southern California, Los Angeles
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RekryterarFas 3
- USC Norris Comprehensive Cancer Center, Los Angeles
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RekryterarFas 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
RekryterarFas 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RekryterarFas 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekryterarFas 1/2
- START Los Angeles, Los Angeles
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
RekryterarFas 1
- The Angeles Clinic, Los Angeles
- UCLA, Los Angeles
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RekryterarFas 1/2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Project: Every Child for Younger Patients With Cancer
RekryterarObservationsstudie
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekryterarFas 1/2
- Children's Hospital Los Angeles, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekryterarFas 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
RekryterarFas 1/2
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
RekryterarFas 1
- The Angeles Clinic and Research Institute, Los Angeles
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
RekryterarFas 1
- START Los Angeles, Los Angeles
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RekryterarFas 1/2
- Los Angeles Cancer Network, Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekryterarFas 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
The Multicentre Selective Lymphadenectomy Trial - 3
Rekryterar
- Cedars-Sinai Medical Centre, Los Angeles
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RekryterarFas 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RekryterarFas 1/2
- UCLA Medical Center, Los Angeles
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RekryterarFas 2
- USA06-0, Los Angeles
- USA16-0, Los Angeles
Neoadjuvant Darovasertib in Primary Uveal Melanoma
RekryterarFas 3
- Jules Stein Eye Institute, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekryterar
- Oncology Institute for Hope and Innovation, Los Angeles
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RekryterarFas 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
RekryterarFas 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RekryterarFas 2/3
- The Angeles Clinic and Research Institute, Los Angeles
- University of California Los Angeles, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RekryterarFas 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RekryterarFas 2
- The Angeles Clinic at Cedars Sinai, Los Angeles
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RekryterarFas 1/2
- Research Site 125, Los Angeles
- Research Site 133, Los Angeles
- Research Site 103, Los Angeles
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RekryterarFas 1/2
- UCLA Health, Los Angeles
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RekryterarFas 1/2
- The Angeles Clinic and Research Institute, Los Angeles
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Rekryterar
- Los Angeles General Medical Center, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
- och 2 fler
Melanom-studier i andra städer
- Houston, TX59 studier
- New York City, NY38 studier
- Nashville, TN33 studier
- Pittsburgh, PA31 studier
- Boston, MA26 studier
- Philadelphia, PA23 studier
- San Francisco, CA22 studier
- Columbus, OH21 studier
- Durham, NC21 studier
- Atlanta, GA21 studier
- Salt Lake City, UT21 studier
- St. Louis, MO21 studier
Andra studier i Los Angeles
- Icke-småcellig lungcancer87 studier
- Cancer (alla typer)74 studier
- Bröstcancer73 studier
- Prostatacancer61 studier
- Kolorektal cancer59 studier
- Metastaserande cancer57 studier
- Äggstockscancer50 studier
- Lungcancer45 studier
- Plattenepitelcancer i huvud och hals42 studier
- Bukspottkörtelcancer35 studier
- Endometriecancer34 studier
- Triplenegativ bröstcancer27 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.